American Society of Hirudotherapy

Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy

Case report published in Annals of Pharmacotherapy (2009)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportClinical TrialsDrug DevelopmentMueller SW et al. · Annals of Pharmacotherapy, 2009

Abstract

OBJECTIVE: To describe a case of successful bivalirudin use as a prefilter anticoagulant in continuous venovenous hemofiltration (CVVH). CASE SUMMARY: A 30-year-old male was brought to the hospital by ambulance with an anterior communicating artery subarachnoid hemorrhage, signs of intraparenchymal hemorrhage, and hydrocephalus. During the patient's complicated hospital course, he developed acute renal failure requiring CVVH, as well as hepatic insufficiency (Child-Pugh class B). Unfractionated heparin was used as a prefilter anticoagulant. After he had a positive heparin-induced thrombocytopenia (HIT) antibody test, prefilter heparin was discontinued in favor of bivalirudin. Filter survival and systemic activated partial thromboplastin time (aPTT) values were compared between prefilter heparin (n = 5) and bivalirudin (n = 4). Filter survival was similar (median 26 h with heparin vs 37 h with bivalirudin; p = 0.52). Prefilter bivalirudin 1-2.5 mg/hour (0.009-0.023 mg/kg/h) was effective in maintaining systemic aPTTs that were 1-1.4 times the reference range. Serotonin release assay and subsequent HIT antibodies were negative. The patient's renal function improved and CVVH was discontinued. DISCUSSION: Critically ill patients requiring CVVH often need regional or systemic anticoagulation to prevent filter occlusion. In some patient populations, such as those with HIT or liver failure, prefilter heparin and regional citrate, respectively, may not be options. Alternative anticoagulants may be needed to avoid complications of frequent filter occlusions. The direct thrombin inhibitors (DTIs) lepirudin and argatroban have been used to maintain hemofilter patency, in small studies. Bivalirudin may have pharmacokinetic advantages over other DTIs when used in patients with hepatic and renal impairment. In our patient, bivalirudin provided a safe alternative to heparin therapy and was effective in maintaining hemofilter patency during CVVH. CONCLUSIONS: Prefilter bivalirudin may be an option to prevent filter occlusion in patients requiring continuous renal replacement therapy. Future studies are needed to validate the safety and efficacy of bivalirudin as a prefilter anticoagulant.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAcute Kidney InjuryAdultAnticoagulantsHemofiltrationHeparinHirudinsHumansMalePeptide FragmentsRecombinant ProteinsThrombocytopenia

Summary

Case using prefilter bivalirudin 1–2.5 mg/h to maintain hemofilter patency during CVVH in HIT patient with hepatic and renal impairment; filter survival 37 h with bivalirudin vs 26 h with heparin.

Why This Matters for Hirudotherapy

This case report describes the successful use of bivalirudin as a prefilter anticoagulant in continuous venovenous hemofiltration for a 30-year-old male with acute renal failure, hepatic insufficiency, and suspected heparin-induced thrombocytopenia. Bivalirudin provided effective maintenance of hemofilter patency and systemic anticoagulation, with filter survival comparable to heparin. The abstract discusses bivalirudin as one of several direct thrombin inhibitors alongside lepirudin and argatroban, but makes no mention of leeches, hirudin's natural origin, the leech secretome, or hirudotherapy. This is a single-case pharmaceutical report with no involvement of leeches or leech therapy, so its relevance to ASH is indirect at best.

Citation

Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy.

Mueller SW et al. · Annals of Pharmacotherapy, 2009

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.